Risperidone use in chronic Schizophrenia tied to lower Metabolic Syndrome Risk compared to olanzapine: Study

A new study published in the Pakistan Journal of Pharmaceutical Sciences showed that long-term use of risperidone in chronic schizophrenia is associated with a lower risk of metabolic syndrome when compared to olanzapine. However, high risk patients should undergo regular metabolic monitoring and may benefit from additional supportive interventions to reduce complications.

Antipsychotic medications are essential in managing schizophrenia, but their prolonged use has long been associated with adverse metabolic effects, including weight gain, impaired glucose tolerance, and lipid abnormalities. While these risks are well documented in Western populations, data from Chinese cohorts have remained relatively scarce, which prompted this investigation.

This cross-sectional study analyzed 160 chronic schizophrenia patients, who were divided evenly into two groups based on their long-term treatment, as patients receiving Risperidone or Olanzapine. The team assessed the prevalence of metabolic syndrome using criteria established by the International Diabetes Federation, along with detailed evaluations of glucose metabolism, lipid levels, and physical measurements like body mass index (BMI), waist circumference, and blood pressure.

The patients treated with risperidone showed a significantly lower prevalence of metabolic syndrome (30.0%) when compared to the olanzapine group (48.8%). This difference was statistically significant, pointing towards a potentially safer metabolic profile for risperidone in long-term use.

Beyond overall prevalence, the risperidone group also demonstrated better control over key metabolic markers. Measures of blood glucose and lipid levels were significantly improved when compared to those observed in patients taking olanzapine. These findings suggest that risperidone may exert less disruptive effects on metabolic processes.

However, the study also illuminated that metabolic concerns persist regardless of the medication used. Both groups expressed elevated BMI, increased waist circumference, and higher blood pressure levels, that contribute to long-term health risks.

The findings of this research emphasize the need for informed clinical decision-making, yet, this cannot replace individualized care. The choice of antipsychotic treatment often involves balancing psychiatric efficacy with physical health risks, and what works best can vary widely between patients.

Overall, this research suggest that regular metabolic monitoring is imperative in individuals undergoing long-term antipsychotic therapy. Routine screening for weight changes, blood sugar, and lipid levels, along with lifestyle modifications such as diet and exercise, can play a crucial role in reducing the burden of metabolic complications.

Source:

Wu, Y., Wu, J., Deng, Z., & Xiao, T. (2026). Metabolic syndrome in chronic schizophrenia: Cross-sectional hospital assessment of prolonged risperidone exposure. Pakistan Journal of Pharmaceutical Sciences, 39(6), 1888-1900. https://doi.org/10.36721/PJPS.2026.39.6.180.1